1 /
1
Uniphyllin Continus Tablets 400 mg
Description：
- 400 mg
Product info :
- Must be prescribed by Health Professional
Therapeutic Indication Pharmaceutical Form Qualitative and
Quantitative Composition Dose and
Administration
Quantitative Composition Dose and
Administration
Therapeutic Indication
Asthma and COPD
In the treatment and prophylaxis of bronchospasm and inflammation associateed with asthma, chronic bronchitis and emphysema. Also indicated in adults for the treatment of cardiac asthma and left ventricular or congestive cardiac failure.
Pharmaceutical Form
Appearance
Capsule shaped, white, modified- release tablet with UNIPHYLLIN on one side and Napp logo and U400 on either side of a scoreline on the reverseHealth Insurance Code
BC19557100License
衛署藥輸字第019557號Dose and Administration
Oral: A controlled- released tablet are not to be chewed or crushed, because that may lead to a rapid release of aminophylline with the potenial of toxicity.
The tablet may be halved, if required during the initial week of therapy or for dose titration.
The tablet may be halved, if required during the initial week of therapy or for dose titration.
Adults and the elderly: The usual maintenance dose for adults and elderly patients is 200mg 12 hourly. This may be titrated either 300mg or 400mg dependent on the therapeutic response.
Plasma theophylline concentration should ideally be maintained between 5 and 15mg/L. A plasma level of 5ml/L probably represents the lower level of clinical effectiveness. Significant adverse reactions are usually seen at plasma theophylline levels greated than 20mg/L. Patients may require monitoring of plasma theophylline levels when higher dosages are prescribed or when co-administered with medication that reduced theophylline clearance.
Children: The maintenance dose is 9mg/kg twice daily.
Some children with chronic asthma require and tolerate much higher doses (10-16mg/kg twice daily).
Lower dosages (Based on usual adult dose) may be required for adolescents.
It may be appropriate to administer a larger evening or morning dose in some patients, in order to achieve optimum therapeutic effect when symptoms are most severe e.g. at the time of the "morning dip" in the lung function.
In patients whose nigh time or day time symptoms persist despite other therapy and who are not currently receiving theophylline, then the total daily requirement of UNIPHYLLIN CONTINUS tablet (as specified above) may be added to their treatment regimen as either a single evening or morning dose.
Plasma theophylline concentration should ideally be maintained between 5 and 15mg/L. A plasma level of 5ml/L probably represents the lower level of clinical effectiveness. Significant adverse reactions are usually seen at plasma theophylline levels greated than 20mg/L. Patients may require monitoring of plasma theophylline levels when higher dosages are prescribed or when co-administered with medication that reduced theophylline clearance.
Children: The maintenance dose is 9mg/kg twice daily.
Some children with chronic asthma require and tolerate much higher doses (10-16mg/kg twice daily).
Lower dosages (Based on usual adult dose) may be required for adolescents.
It may be appropriate to administer a larger evening or morning dose in some patients, in order to achieve optimum therapeutic effect when symptoms are most severe e.g. at the time of the "morning dip" in the lung function.
In patients whose nigh time or day time symptoms persist despite other therapy and who are not currently receiving theophylline, then the total daily requirement of UNIPHYLLIN CONTINUS tablet (as specified above) may be added to their treatment regimen as either a single evening or morning dose.